Ping Mu, Ph.D.
The University of Texas Southwestern Medical Center
|Titles & Positions|
|Institutional & Related Links|
|Grant ID: RR170050|
Recruitment of First-Time, Tenure-Track Faculty Members
Memorial Sloan-Kettering Cancer Center
August 16, 2017
Ping received his B.S. in Biotechnology from Peking University, Beijing, China. He earned his Ph.D. in Biomedical Sciences (Cancer Biology) from Weill Cornell Medical College, where he worked with Dr. Andrea Ventura. Ping identified a microRNA called miR-19 as a crucial oncogenic driver of Myc-driven B cell lymphoma and prostate cancer. This work provided the key rationale for targeting miR-19 to treat these two cancers.
In 2013, Ping joined the laboratory of Dr. Charles L. Sawyers as a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, New York. There, he identified a novel mechanism of antiandrogen resistance in prostate cancer mediated by increased lineage plasticity, or “identity fraud”. This lineage plasticity is enabled by the activation of SOX2 and can be reversed by SOX2 inhibition, which raises the hope that appropriate clinical intervention of lineage plasticity could prevent or overcome resistance.